

**$\alpha$ 7 nicotinic acetylcholine receptor signaling modulates ovine fetal brain astrocytes transcriptome in response to endotoxin: comparison to microglial transcriptome, implications for prenatal stress and development of autism spectrum disorder**

M. Cao<sup>1</sup>, J.W. MacDonald<sup>7</sup>, H.L. Liu<sup>1</sup>, M. Weaver<sup>8</sup>, M. Cortes<sup>2</sup>, L.D. Durosier<sup>1</sup>, P. Burns<sup>4</sup>, G. Fecteau<sup>4</sup>, A. Desrochers<sup>4</sup>, J. Schulkin<sup>6</sup>, M. C. Antonelli<sup>9</sup>, Bernier, R.A.<sup>10</sup>, M. Dorschner<sup>8</sup>, T. K. Bammler<sup>7</sup>, M.G. Frasch<sup>1,2,6</sup>

<sup>1</sup>Dept. of Obstetrics and Gynaecology and Dept. of Neurosciences, CHU Ste-Justine Research Centre, Faculty of Medicine, Montréal, QC, Canada;

<sup>2</sup>Animal Reproduction Research Centre (CRR), Faculty of Veterinary Medicine, Université de Montréal, Montréal, QC, Canada;

<sup>4</sup>Dept. of Clinical Sciences, Faculty of Veterinary Medicine, Université de Montréal, QC, Canada;

<sup>6</sup>Dept. of Obstetrics and Gynecology, University of Washington, Seattle, WA, USA.

<sup>7</sup> Dept. of Environmental and Occupational Health Sciences, University of Washington, Seattle, WA, USA

<sup>8</sup> UW Medicine Center for Precision Diagnostics, University of Washington, Seattle, WA, USA

<sup>9</sup> Instituto de Biología Celular y Neurociencia “Prof. Eduardo De Robertis”, Facultad de Medicina, Universidad de Buenos Aires, Argentina

<sup>10</sup> Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA

**Running head:** Fetal astrocytes  $\alpha$ 7nAChR signaling

Address of correspondence:

Martin G. Frasch

Department of Obstetrics and Gynecology

University of Washington

1959 NE Pacific St

Box 356460

Seattle, WA 98195

Phone: +1-206-543-5892

Fax: +1-206-543-3915

Email: [mfrasch@uw.edu](mailto:mfrasch@uw.edu)

**Conflict of interest statement:** The authors have declared that no conflict of interest exists

## ABSTRACT

Neuroinflammation *in utero* may result in lifelong neurological disabilities. Astrocytes play a pivotal role, but the mechanisms are poorly understood. No early postnatal treatment strategies exist to enhance neuroprotective potential of astrocytes. We hypothesized that agonism on  $\alpha 7$  nicotinic acetylcholine receptor ( $\alpha 7$ nAChR) in fetal astrocytes will augment their neuroprotective transcriptome profile, while the antagonistic stimulation of  $\alpha 7$ nAChR will achieve the opposite. Using an *in vivo* - *in vitro* model of developmental programming of neuroinflammation induced by lipopolysaccharide (LPS), we validated this hypothesis in primary fetal sheep astrocytes cultures re-exposed to LPS in presence of a selective  $\alpha 7$ nAChR agonist or antagonist. Our RNAseq findings show that a pro-inflammatory astrocyte transcriptome phenotype acquired *in vitro* by LPS stimulation is reversed with  $\alpha 7$ nAChR agonistic stimulation. Conversely, antagonistic  $\alpha 7$ nAChR stimulation potentiates the pro-inflammatory astrocytic transcriptome phenotype. Furthermore, we conduct a secondary transcriptome analysis against the identical  $\alpha 7$ nAChR experiments in fetal sheep primary microglia cultures and against the Simons Simplex Collection for autism spectrum disorder and discuss the implications.

**WORD COUNT:** 163

## Introduction

Mechanisms of astrocytes' contribution to fetal neuroinflammation are poorly understood.  $\alpha 7$  nicotinic acetylcholine receptor ( $\alpha 7$ nAChR) signaling may polarize adult brain's glia towards a neuroprotective role under inflammatory conditions such as lipopolysaccharide (LPS) exposure, but the role of this receptor in fetal brain's glia cells yet remains to be elucidated.(1–6)

Shytle et al. showed that  $\alpha 7$ nAChR signaling in microglia may be involved in the modification of microglial activation towards a neuroprotective role by suppressing the inflammatory state and strengthening the protective function.(7)

TNF- $\alpha$  and HMGB1 are released mainly by microglia and astrocytes around the injured area.(8,9) LPS-induced release of large amounts of TNF- $\alpha$  from microglia leads to inflammation and possibly neuronal destruction. HMGB1 released by neurons into the extracellular space signals necrosis and activates immune competent cells and astrocytes.(10)

Astrocytes express  $\alpha 7$ nAChR and acquire a specific reactive phenotype when exposed to HMGB1 or LPS (11), but also potentiate microglial activation when the two types of cells are co-cultured *in vitro*.(12–14) These findings suggest that HMGB1/astrocyte interaction plays a key functional role in the progression of inflammatory processes in the brain by facilitating local leukocyte infiltration. In contrast,  $\alpha 7$ nAChR signaling inhibits LPS-induced TNF- $\alpha$  and interleukin-1 $\beta$  (IL-1 $\beta$ ) release by microglia.(7) Vagal afferent signaling affects widely distributed areas of the brain via Nucleus tractus solitarii, and studies indicate that stimulation of the vagus nerve activates many neurons in both cerebral hemispheres and hippocampus.(15,16) We showed that vagal signaling decreases HMGB1 concentrations in neuronal and astrocyte cytoplasm expressing  $\alpha 7$ nAChR and decreases microglial activation, which may decrease glial priming.(4) Thus, efferent peripheral or afferent vagal activity may mediate central neuroprotection and modulate the magnitude of the brain's inflammatory response towards a lower setpoint of baseline inflammatory activity. In the developing brain this implies more than control of neuroinflammation, because microglia and astrocytes also shape the neuronal development, including synaptogenesis, thus impacting future susceptibility to adult brain's diseases.

We hypothesized that (1) under exposure to LPS,  $\alpha 7$ nAChR agonist stimulation in fetal astrocytes augments their neuroprotective profile, while the antagonistic stimulation reduces it; (2) a LPS double-hit (first *in vivo*, then *in vitro*) on astrocytes exacerbates these effects similar to microglia as demonstrated before.(2) Using an *in vivo* - *in vitro* fetal sheep model (17), we validate these hypotheses via RNASeq analysis in primary fetal astrocyte cultures exposed to LPS in the presence of a selective  $\alpha 7$ nAChR agonist or antagonist. We compare these findings to the previously published results in identically conducted microglia experiments.(2,18)

**Word count: 419**

## Methods

### Study approval

This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The respective *in vivo* and *in vitro* protocols were approved by the Committee on the Ethics of Animal Experiments of the Université de Montréal (Permit Number: 10-Rech-1560).

### Astrocytes isolation and purification

Fetal sheep brain tissues were obtained during sheep autopsy after completion of the *in vivo* experiment to conduct the *in vitro* study (Fig. 1). The non-instrumented, untreated twins were designated “naïve” (no LPS exposure *in vivo*). Instrumented animals that received LPS *in vivo* were used for second hit LPS exposure *in vitro*.

The detailed protocol has been presented elsewhere.(2) Briefly, astrocytes are the major adherent cell population in flask. Astrocytes were purified by passage into a new T75 flask for 4-5 times before any manipulations and treatments. After floating microglia collection, the adherent cells were detached by trypsinization (Trypsine 0.25% + EDTA 0.1%, Wisent Cat. No 325-043-EL) and re-plated into a new flask. Cells were cultured for another 7 days with 10% all-dressed DMEM. The cell passage procedure took 4-5 weeks until purified astrocytes could be used for the *in vitro* experiment.

Pure astrocytes were plated into a 24-well plate at  $1 \times 10^5$  cells/mL with 10% DMEM for another 7 days, and then treated with or without LPS for 6h.

Cell-conditioned media were collected for cytokine analysis. To verify astrocytes purity, a portion of cells was plated into Lab-Tek 8 well chamber glass slide (Thermo Scientific) for immunocytochemistry (ICC) analysis. Glial fibrillary acidic protein (GFAP) was used as an astrocyte marker; cells were counterstained with Hoechst.(18)



**Figure 1. Experimental design of modulating glial  $\alpha 7$ nAChR signaling in a double-hit fetal sheep model.** *In vivo*, *in vitro* and RNAseq experiments are illustrated. *In vivo* study includes Control (saline) or LPS-exposed sheep fetuses. For the *in vitro* study, cultured cells (microglia or astrocytes) were derived from an *in vivo* Control animal, named Naïve, or from an *in vivo* LPS-exposed animal, named second hit (SH). There are 8 experimental groups: naïve Control (NC), naïve LPS (NL), naïve exposed to  $\alpha$ -Bungarotoxin (NB), naïve exposed to AR-R17779 (NA), and each respective second-hit groups (SH). Reproduced with permission.(19)

### *Astrocyte cell culture and treatment*

Prior to exposure to LPS, cells were pretreated for 1 hour with either 10nM AR-R17779 hydrochloride (Tocris Bioscience Cat# 3964), a selective  $\alpha 7$ nAChR agonist, or 100 nM  $\alpha$ -Bungarotoxin (Tocris Bioscience Cat# 2133), a selective  $\alpha 7$ nAChR antagonist. Optimal dose of AR-R17779 (A) or  $\alpha$ -Bungarotoxin (B) was chosen based on a dose-response experiment with LPS; AR-R17779 hydrochloride was dissolved in DMSO into a stock solution.  $\alpha$ -Bungarotoxin was reconstituted with culture media into a stock solution and underwent serial dilutions. AR-R17779 and  $\alpha$ -Bungarotoxin preparations were added well by well; the same volume of vehicle (either DMSO or cell culture media) was added in control wells. Therefore, in a complete cell culture experiment, we had four experimental groups: Control (naïve control or NC), LPS (naïve LPS or NL), LPS+B (naïve LPS+B or NB) and LPS +A (naïve LPS+A or NA). Second hit cell cultures were designed with the same pattern and divided into four experimental groups: Control (SHC), LPS (SHL), LPS+B (SHB) and LPS+A (SHA).

### *Measurement of cytokines in cell culture media*

The approach is described elsewhere.(17,19) Briefly, cytokine concentrations in cell culture media (IL-1 $\beta$ ) were determined by using an ovine-specific sandwich ELISA. 96-well plates (Nunc Maxisorp, high capacity microtitre wells) were pre-coated with the capture antibody, the mouse anti sheep monoclonal antibodies (IL-1 $\beta$ , MCA1658, Bio Rad AbD Serotec) at a concentration of 4 $\mu$ g/ml on an ELISA plate at 4°C overnight. After 3 times wash with washing buffer (0.05% Tween 20 in PBS, PBST), plates were blocked for 1h with 1% BSA in PBST for plasma samples or 10% FBS for cell culture media. Recombinant sheep proteins (IL-1 $\beta$ , Protein Express Cat. no 968-405) were used as ELISA standard. All standards and samples (50 $\mu$ l per well) were run in duplicates. Rabbit anti-sheep polyclonal antibodies (detection antibody IL-1 $\beta$ , AHP423, Bio Rad AbD Serotec) at a concentration of 4 $\mu$ g/ml were applied in wells and incubated for 30 min at room temperature. Plates were washed with washing buffer for 5-7 times between each step. Detection was accomplished by assessing the conjugated enzyme activity (goat anti-rabbit IgG-HRP, dilution 1:5000, Jackson ImmunoResearch, Cat. No 111-035-144) via incubation with TMB substrate solution (BD OptEIA TMB substrate Reagent Set, BD Biosciences Cat. No 555214); colour development reaction was stopped with 2N sulphuric acid. Plates were read on an ELISA plate reader at 450 nm, with 570 nm wavelength correction (EnVision 2104 Multilabel Reader, Perkin Elmer). The sensitivity of IL-1 $\beta$  ELISA for media was 41.3 pg/ml. For all assays, the intra-assay and inter-assay coefficients of variance were <5% and <10%, respectively.

### *RNAseq approach*

Nine replicates of astrocyte culture were studied, with one control and three treatment groups (Ctrl, LPS100, LPS+A10, LPS+B100) per replicate. Four randomly chosen replicates were used for RNAseq. With one treatment missing in one of the replicates (SHA), fifteen samples in total were assessed with RNAseq in this study (Table 1).

RNA extraction and RNA quantification: We used Qiagen RNeasy Mini Kit (Cat no 74104) for RNA extraction. RNA quantity and quality (RNA integrity number, RIN) was established by using

a RNA Nano Chip (Agilent RNA 6000 Nano Chips) with Agilent 2100 BioAnalyzer. All samples had an acceptable RIN value ranging from 8.4 to 9.6. A total of twelve naïve astrocyte cultures from four sets of replicates was selected for RNA sequencing at high throughput, as well as three second hit astrocyte cultures, including SHC, SHL and antagonist-exposed astrocytes (SHB).

RNA-seq libraries were prepared using the TruSeq stranded mRNA kit (Illumina cat #20020594) and quality control was performed on the Agilent TapeStation and using the KAPA SYBRFAST qPCR kit. Single read 100-bp sequencing was performed in rapid mode on a HiSeq 2500 at the University of Washington Northwest Clinical Genomics Lab (Department of Pathology).

#### *RNAseq data analysis*

The goal for this analysis was to compare the single hit LPS treated samples to Control, as well as making comparisons between the LPS treated samples (e.g., testing for changes due to the additional agonist or antagonist treatment). The second hit samples had no replicates, so we could only make the directed comparisons between the single and second hit samples. For example, comparing the single and second hit LPS treated samples, as before.(2)

We aligned the reads to the Oar\_v3.1 transcriptome using the salmon aligner (20), which infers the most likely transcript for each read using a quasi-mapping algorithm. We then ‘collapsed’ the transcript read counts to the gene level by summing up the reads for each gene’s transcripts, using the Bioconductor tximport package.(21) In the end, we had a set of read counts per gene, for each sample.

We also made comparisons to the existing RNAseq data that were generated using fetal sheep microglia. The microglia samples we used were published elsewhere and the data set is also accessible online.(17)

**Table 1. Sample inventory for RNAseq study in astrocytes samples.**

<b>Sample</b>	<b>Treatment</b>	<b>Hit number</b>
4414T1	Ctrl	1
4414T1	LPS100	1
4414T1	LPS+B100	1
4414T1	LPS+A10	1
4414T2	Ctrl	1
4414T2	LPS100	1
4414T2	LPS+B100	1
4414T2	LPS+A10	1
4502P	Ctrl	1
4502P	LPS100	1
4502P	LPS+B100	1
4502P	LPS+A10	1
711P	LPS100	2
711P	LPS+B100	2

To make comparisons we used the Bioconductor edgeR package (22), using the quasi-likelihood modeling functions, which incorporate both a negative binomial dispersion estimate based on all genes, plus a quasi-likelihood dispersion estimate based on each gene, with an empirical Bayes adjustment. This is similar to the commonly used generalized linear model (GLM) based on a negative binomial link function (used by e.g., DESeq2 and edgeR), but is more conservative because it also incorporates the gene-wise variance estimates.(23)

We fitted the model described above, including a blocking effect for each animal, and made the comparisons, incorporating a 1.5-fold change criterion into the test using the edgeR glmTreat function. In other words, instead of testing against the null hypothesis that the difference between groups is zero, we tested against the null hypothesis that the difference was less than 1.5-fold. We then selected genes based on a false discovery rate (FDR) < 0.05, meaning that we expect that there are, at most, 5% false positives in our set of significant genes.

Ingenuity Pathway Analysis (IPA, Qiagen, 2018) was used for identification of signaling pathways unique to each treatment.

The raw RNAseq data has been deposited under GEO accession number GSE123713.

### *Statistical analyses*

GEE modeling approach was used to assess the effects of LPS and drug treatments on IL-1 $\beta$ . We used a linear scale response model with LPS/drug treatment group (main term “treatment”) and presence or absence of second hit exposure (main term “hit”) as predicting factors to assess their interactions using maximum likelihood estimate and Type III analysis with Wald Chi-square statistics. SPSS Version 25 was used for these analyses (IBM SPSS Statistics, IBM Corporation, Armonk, NY). Significance was assumed for  $p < 0.05$ . Results are provided as median {25-75} percentiles. Not all measurements were obtained for each animal studied, as indicated.


**Word count: 1563**

## Results and Discussion

### Cytokine secretion profile

Overall, regardless of drug pretreatment, LPS induced IL-1 $\beta$  increase. Surprisingly, the LPS response, was lower in the second hit astrocytes cultures compared to single hit (main term “hit”  $p=0.010$ , Fig. 2).

While we did not detect a significant interaction with the number of LPS hits (“treatment \* hit” interaction term  $p=0.227$ ), the treatment had an overall effect on IL-1 $\beta$  secretion in cultures (main term “treatment”  $p=0.019$ ).



**Figure 2.** IL-1 $\beta$  secretion in ovine primary astrocyte cultures in response to six hours LPS exposure without or with pre-incubation with  $\alpha 7$ nAChR antagonist (B100) or agonist (A10) for one hour. Single hit, *in vitro* only LPS exposure; second hit, *in vivo* systemic and subsequent *in vitro* LPS exposure four to five weeks later. Y axis shows fold changes in IL-1 $\beta$  in relation to baseline secretion levels on log scale. GEE model results are presented in text and no significance marks are provided in the figure. Briefly, we found significant main term effects ( $p=0.019$ ) “treatment” (LPS and  $\alpha 7$ nAChR drug) as well as main term “hit” ( $p=0.010$ ), *i.e.*, the contribution of *in vivo* LPS exposure, the second hit effect on the IL-1 $\beta$  secretion profile. Results are provided as median {25-75} percentiles.

### Whole transcriptome analysis

Mapped reads aligned to any transcript from the Oar\_v3.1 transcriptome at 66% which is good. PCA analysis showed large differences between the different treatment groups, and much smaller differences within each group, indicating that we have a good signal with likely many differentially expressed genes (DEG) to be found.

We present the number of genes for each comparison in the Table 2 below.

**Table 2. Differentially expressed genes from the fetal sheep astrocytes whole transcriptome analysis.**


Comparison	Number significant
LPS100_1_hit vs Ctrl_1_hit	1835
LPS+A10_1_hit vs Ctrl_1_hit	1724
LPS+B100_1_hit vs Ctrl_1_hit	1742
LPS+A10_1_hit vs LPS100_1_hit	273
LPS+B100_1_hit vs LPS100_1_hit	0



LPS+A10_1_hit vs LPS+B100_1_hit	292
LPS100_1_hit vs LPS100_2_hit	3759
LPS+A10_1_hit vs LPS+A10_2_hit	3308
LPS+B100_1_hit vs LPS+B100_2_hit	3858

Number of significant genes in astroglia samples at an FDR < 0.05 and a 1.5-fold change.

Principal component analysis showed two transcriptome clusters (Fig. 3): control, LPS single-hit and second-hit astrocytes pre-treated with  $\alpha 7$ nAChR agonist and LPS single-hit and second-hit astrocytes pre-treated with  $\alpha 7$ nAChR antagonist. That is, a pro-inflammatory transcriptome astrocyte phenotype acquired *in vivo* or *in vitro* by LPS stimulation is reversed with  $\alpha 7$ nAChR agonistic stimulation. Conversely, antagonistic  $\alpha 7$ nAChR stimulation potentiates the pro-inflammatory astrocytic phenotype.



**Figure 3.** Static 3D plot of the astrocyte RNA-Seq data with single and double-hit LPS treatment. The angle of the plot was chosen to give the best viewpoint to show differences between the sample types. Note that controls and  $\alpha 7$ nAChR agonistically pre-treated astrocytes cluster together and separately from those exposed to LPS w/o or with antagonistic  $\alpha 7$ nAChR pre-treatment. Note here that there are three of the LPS\_100\_1\_hit samples in the plot shown in Fig. 3; it just so happens that the third sample is obscured by the uppermost LPS+B100\_1\_hit sample.

The top down-regulated signaling pathway unique to LPS treatment was Ephrin A signaling (p-value 5.77E-04).  $\alpha 7$ nAChR agonist reduced this down-regulation (p-value 2.51E-02).  $\alpha 7$ nAChR antagonist had no significant effect. Ephrin signalling has been implicated in neuroprotective astrocyte phenotype.(24) Our findings suggest a neuroprotective effect of  $\alpha 7$ nAChR agonism on ephrin signaling pathway.

Consistent with the notion of cholinergic signaling involved in stress axis regulation (2), POMC was the second highest up-regulated gene, with a log ratio of 3.387.

In comparison, microglia exposed to LPS regardless  $\alpha 7$ nAChR manipulation showed a single DEG: SLC1A2 up-regulated 3.53 (FDR 5.17E-04). The LPS second-hit scenario did not change the overall pattern;  $\alpha 7$ nAChR agonist in astrocytes exposed to LPS *in vivo* also showed a -0.806 down-regulation of SH3GL1 (endophilin-A2, FDR 4.74E-02) which is involved in brain development, endocytic trafficking of AMPA-glutamate receptors, synaptic plasticity and serves beta-1 adrenergic receptor binding, with its role in astrocytes yet to be determined.

**Table 3. Comparison of astrocytes' and microglial transcriptomes**

Comparison	Number significant
LPS100 vs Ctrl	236
LPS+A10 vs Ctrl	285
LPS+B100 vs Ctrl	470
LPS+A10 vs LPS100	1
LPS+B100 vs LPS100	0
LPS+A10 vs LPS+B100	1

Number of significant genes in microglia samples at an FDR < 0.05 and a 1.5-fold change.

#### *Fetal neuroinflammation and stress: a mechanistic link to autism spectrum disorder?*

LPS effects on key genes involved in stress axis activity raised the question about the poorly understood role of astrocytes in the signaling pathways of neuroinflammation and prenatal stress (PS).(25)

Indeed, PS is accompanied by inflammation in the mother and offspring.(25–29) (30) Both, PS and fetal neuroinflammation have been implicated in etiology of autism spectrum disorder (ASD).(31,32) PS increases expression of the glutamate (Glu) transporter vGluT1 (SLC17A7) resulting in higher levels of GLT1.(33,34)

Here, we sought to verify if the exposure of fetal astrocytes to LPS induces upregulation of Glu transporters in glia akin to PS.(33,34)

Given the known relationship between PS and VGLUT1 expression, we used IPA to annotate VGLUT1 gene network with our findings to test for evidence that the network is being perturbed by LPS treatment. Across all treatment comparisons, two DEGs were identified in astrocytes (common to all comparisons): JAK1/2 (2.732 (log ratio) upregulated, FDR 3.91E-05) and SLC1A2 (2.350 upregulated, FDR 1.80E-04). JAK1/2 is involved in glucocorticoid receptor signaling and iron homeostasis signaling pathways, whereas JAK/Stat is involved in IL-6 signaling pathways. SLC1A2 is also known as GLT-1 or glial high affinity glutamate transporter; it is implicated in glutamate receptor signaling and neuroinflammation signaling pathways.(35) Upregulation of glial GLT-1 in hippocampus has been reported after chronic stress due to its control by glucocorticoids.(36–38)

Again assessing the present findings together with the previously published RNAseq data from the identical experiment in ovine fetal microglia (2), we found GLT-1 to be upregulated in microglia and astrocytes regardless cholinergic manipulation. Albeit both pure primary cultures were exposed to LPS, we found the up regulation of JAK1/2 to be unique to astrocytes. This finding is conceptually in line with studies reporting brain cell-specific signalling pathways

behavior in response to IL-1 $\beta$ .(39) Much remains to be learned about the differences between second messenger signaling cascades involved in astrocytes, microglia and neurons in the developing fetal brain exposed to inflammatory stimuli.

#### *Does subclinical neuroinflammation impact genes implicated in ASD?*

To explore the potential connections between fetal neuroinflammation, PS and ASD, and to generate new hypotheses on the contribution of microglial and astrocytes' contribution, we tested for the presence of disruptive mutations to genes involved in pathways associated with stress or inflammatory responses in a large sample of children with ASD.

First, we identified genes associated with inflammatory, stress and metabolic phenotype of microglia and astrocytes. These included genes associated with pathways that regulate microglia or astrocyte activity (Table 4). We then capitalized on the complete published sequencing results from the Simons Simplex Collection (SSC; (40)).

We derived the rationale for including genes involved in energy homeostasis from the observations we others made linking neuroimmune and metabolic memory signatures in fetal microglia exposed to LPS and the larger emerging gestalt of physiological stress response in immunometabolism, in particular by astrocytes.(41,42) Based on our observations in fetal microglia (2,18), the simplistic hypothesis is that exposure to endotoxin or chronic stress augments energy conservation - driving pathways and the  $\alpha$ 7nAChR agonism reduces that response. Consequently, assuming that *in utero* inflammation or stress increase risk for ASD, we expected to identify some genes linked to the ASD diagnosis, which fall into the family of signalling pathways identified in Table 4.

**Table 4. Genes implicated in the signature of astrocytes and microglia exposed to endotoxin or maternal stress**

Groups	Genes	Reference
Glial cell phenotype	TMEM119	Transmembrane protein, identifies resident microglia (from blood-derived macrophages) (43,44)
	TGF $\beta$	Resident microglial biomarker (45,46)
	CD11b	Resident microglial biomarker (44–46)
	CD11c	Activated microglia (45,46)
	CD45	Resident microglial biomarker (44–46)
	Iba1	Ionized calcium binding adaptor molecule 1: Non-specific microglial / macrophage biomarker (4,18,44–46)
Inflammation	HMGB1	Hypermobility group box protein 1, a pleiotropic signaling molecule in glia cells and neurons: a growth factor, a pro-inflammatory molecule (9); implicated in ASD(47)
	IL-10	Key cytokine involved inflammation homeostasis deployed in the cross-talk of microglia and astrocytes (48)
	<b>NLRP3*</b>	Inflammasome activated in ASD (49)
Stress	CRH	Corticotropin-releasing hormone, key hormone linking chronic stress with anxiety (50,51)

	HSD11B1	11 $\beta$ -Hydroxysteroid dehydrogenase type 1(52)
	POMC	Proopiomelanocortin (53)
	p-Akt	Phosphorylated-Akt(54)
	PI3K	PI3K/Akt signaling pathway (54,55)
Energy homeostasis	Cx43	Connexin 43 gap junction maintaining astrocytes' homeostasis via metabolic cooperation (56)
	AMPK	Adenosine monophosphate kinase, intracellular energy sensor(57)
	FBP	Fructo-biphosphokinase: signature of second-hit memory in fetal microglia (18)
	IL-10	Key regulator of neuroimmune homeostasis via cross-talk of microglia and astrocytes (48)
	<b>mTOR*</b>	Mammalian target of the rapamycin signaling pathway (58,59)
Iron homeostasis	HAMP	Hepcidin, regulator of iron homeostasis and inflammation; implicated, along with ferroportin and transferrin, in microglial response to endotoxin interfering with $\alpha$ 7nAChR signaling (2)
	<b>SLC40A1*</b>	Ferroportin gene
	<b>TFR2*</b>	Transferrin receptor 2; involved in iron sequestration
	TFRC	Transferrin receptor protein 1; needed for iron sequestration
	HMOX1	Hemoxygenase 1, key enzyme of iron homeostasis also serves as signature of second-hit memory in fetal microglia and promoted by $\alpha$ 7nAChR agonism (18,60)
Complement pathway	C1QA	Aside of its traditional role in innate immunity (61), elements of the complement pathway are involved in neuronal-glial interactions; recognized as essential players in brain development, especially in synaptogenesis/synaptic pruning and predisposition for neurodegenerative diseases (62,63), their microglial expression is also susceptible to LPS exposure <i>in utero</i> (2)
	C1QB	
	C3AR1	
	CR2	
Epigenetic memory	<b>HDAC*</b> and HAT families	Histone acetylation/deacetylation enzymes: HDAC 1, 2, 3, 7 and 9 found in SSC data base of ASD gene mutations. HDAC <b>1, 2, 4</b> and 6 involved in fetal microglial memory of LPS exposure; HDAC <b>1, 2, 4</b> and <b>7</b> increased with altered neuronal AChE signaling and increased anxiety behavior due to adult chronic stress exposure (2,18,53,55,64,65)
* Hits in the SSC data base		

The SSC is a Simons Foundation Autism Research Initiative funded project with the goal of identifying *de novo* genetic variants associated with ASD. SSC inclusion criteria required that the child meet ASD clinical cutoffs on the Autism Diagnostic Observation Schedule (ADOS;(66)) and on the Autism Diagnostic Interview - Revised (ADI-R; (67)). Additionally, children included in SSC were required to meet the Diagnostic and Statistical Manual of Mental Disorders

(DSM-IV-TR; (68)) diagnostic criteria for ASD. Distribution 15.9 of the SSC contains genetic and phenotypic data for 2759 participants (2384 males) with ASD ages 4-17 years old (mean = 9.0 years) and their family members collected across 12 sites in North America. Exome sequencing results for the SSC have been previously published.(69,70) Published sequencing results were reviewed to identify individuals with a *de novo* likely gene disruptive mutation as defined in Supplementary Table #5 in (70) to any of the above listed genes.

Analysis of the published sequencing data revealed 7 probands and 3 siblings with disruptive *de novo* mutations to 10 genes from the above gene target list. These include SLC40A1 (synonymous mutation in proband); TFR2 (synonymous mutation in sibling); MTOR (missense mutation in proband); NLRP3 (missense mutation in proband); HDAC1 (missense mutation in proband); HDAC2 (synonymous mutation in proband); HDAC3 (intronic indel mutation in sibling); HDAC3 (inframe Indel mutation in proband); HDAC7 (missense mutation in sibling); HDAC9 (missense mutation in proband).

Taken together with the above results on vGlut1 signaling, the findings summarized in Table 4 support our initial hypothesis linking both neuroinflammation and stress exposures *in utero* to etiology of ASD in a gene - environment paradigm: developmental combinations of genetic alterations in key pathways susceptible to environmental stimuli of inflammation or stress increase risk for or, perhaps, cause ASD. Noteworthy, these key pathways include iron and energy homeostasis (Table 4). The implication of iron homeostasis, combined with HDAC-mediated epigenetic memory is particularly intuitive in light of our findings in fetal microglial neuroinflammation (2,18), but has not yet been reported otherwise in conjunction with ASD. We hope these data can be used in future *in vivo* studies to probe mechanistically for the role of these genes in ASD etiology, as part of an early biomarkers panel or as potential therapeutic targets to ameliorate the symptoms. The therapeutic approaches may include early postnatal reprogramming of the effects the intrauterine stress or inflammation exert on brain development using behavioral (e.g., environmental enrichment) or bioelectronic tools.(71)

The salutary mechanisms mediating the therapeutic approaches may involve activation of the afferent cholinergic pathway (cf. Introduction). The efferent wiring of this pathway has begun to unravel in the last decade, while our understanding of the afferent signaling is only beginning to emerge. The efferent component is also referred to as the inflammatory reflex which acts via the cholinergic anti-inflammatory pathway (CAP), a neural mechanism that influences the magnitude of innate immune responses to inflammatory stimuli and maintains homeostasis.(72) Through CAP, increased vagal activity inhibits the release of pro-inflammatory cytokines. We found that spontaneous CAP activity is present in the sheep fetus as early as at 0.76 gestation.(73) Moreover, CAP activation near-term suppresses activation of ovine microglia and astrocytes which express  $\alpha 7$  nAChR or hypoxic-ischemic brain damage in newborn rats.(4,9,74–77) These data suggest that enhancing fetal CAP activity via vagal nerve stimulation or  $\alpha 7$ nAChR agonists might suppress activation of microglia and astrocytes, thus decreasing glial priming and preventing a sustained switch to a reactive phenotype. This might decrease the degree of brain injury sustained from fetal systemic and brain inflammatory responses, thus improving postnatal short- and long-term health outcomes, including susceptibility to ASD.

## General discussion

We found that within its interaction network, GLT-1 was upregulated in microglia and astrocytes regardless of cholinergic manipulation, while the up-regulation of JAK1/2 was unique to astrocytes. This is in line with studies showing brain region specific overexpression of vGluT-1 (SLC17A7) both due to endotoxin stress and due to PS and puts the LPS exposure in the context of a more general brain stress exposure paradigm presenting with shared response patterns of neuroinflammation and metabolic adaptations in astrocytes.(78–80) PS has long lasting consequences on  $\alpha 7$ nACh-ergic signaling in frontal cortex and hippocampus reducing the expression of  $\alpha 7$ nAChR protein expression in the brain of adult rats.(78)

It is plausible to conclude that low grade neuroinflammation results in changes similar to PS with regard to reprogramming glial cells to a higher glutamine uptake. PS and exposure to endotoxin may act synergistically to exacerbate the impairment of neuron-glial glutamatergic interaction. For endotoxin exposure, this process is not subject to cholinergic modulation. Whether or not PS effects alone on astrocytes glutamine uptake can be ameliorated or reversed by  $\alpha 7$ nAChR agonism remains to be investigated.

LPS exposure had the anticipated effect of increasing IL-1 $\beta$  production in astrocytes and we observed this consistently on the transcriptome level. However, our findings on protein level following pre-incubation with  $\alpha 7$ nAChR antagonist or agonist do not align with those on the transcriptome level: present results on protein level do not show a clear effect of  $\alpha 7$ nAChR agonism or antagonism on LPS secretion in ovine fetal astrocytes. Such discordant behavior on protein and transcriptome levels has been reported and studied systematically to represent the rule rather than an exception to cellular biology in general.(81)

The phylogenetically conserved interaction between neuroinflammation and chronic stress has been subject of multiple studies (25), yet we are only beginning to unravel the complex web of interactions, across developmental stages, organs, cell types and species-specific differences, which connect these two phenomena in a mechanistic way. While the role of microglia in this context has been appreciated, the response of astrocytes we report here and their habituated response behavior on protein level under second hit scenario are novel observations warranting further studies in different species.

Future studies will need to explore the protein responses in more depth and in different species to further delineate astrocytic behavior under  $\alpha 7$ nAChR stimulation, especially the peculiarly opposite effect of endotoxin memory in astrocytes compared to microglia on IL-1 $\beta$  secretion.

Microglia - astrocyte ensemble interactions need to be studied to bridge the methodological gap between *in vitro* experimental design and the *in situ* physiology. This can be done in co-cultures, feasible in ovine species, for example.(17) Recent study in mice highlighted the importance of microglia - astrocyte interactions for understanding the polarization dynamics of astrocytes.(82)

It is plausible to conclude that low grade neuroinflammation results in changes similar to those induced by PS with regard to reprogramming astrocytes to a higher glutamine uptake. As shown elsewhere (83), PS and exposure to endotoxin may act synergistically to exacerbate the impairment of neuron-glial glutamatergic interaction. This process is not subject to cholinergic modulation.

Future studies should address the question whether we can implicate an interaction with the CRH receptor 1, because in addition to our hits in the SSC data base of ASD genetics, findings in a rodent model show that cholinergic signalling can reduce stress responsiveness via this receptor with positive behavioural changes. (84)

In summary, we show that genes involved in stress memory of the offspring are also impacted by LPS stress, this impact is further altered by a second hit (memory) and that such memory of LPS stress is amenable to cholinergic treatment via  $\alpha 7$ nAChR. It remains to be validated in future studies whether and which stimulation of the  $\alpha 7$ nAChR is favourable.

**WORD COUNT: 2928**

## **AUTHOR CONTRIBUTIONS**

MCa, PB, GF, AD, and MGF are responsible for the conception and design.

MCa, MCo, HLL, MW, LDD, PB, GF, AD and MGF acquired data.

MCo, MCa, HLL, MW, JWM, MD, TKB, JS and MGF did the analysis and interpretation of data.

MCo, MCa, JWM, TKB and MGF drafted the manuscript.

MCo, MCa, MW, JWM, JS, MCA, TKB and MGF are responsible for revising it for intellectual content.

MCo, MCa, HLL, MW, LDD, JWM, PB, GF, AD, JS, MCA, TKB, MD and MGF gave final approval of the completed manuscript.

**Funding:** Supported by grants from the Canadian Institute of Health Research (CIHR) (MGF); Fonds de la recherche en santé du Québec (FRSQ) (MGF) and Molly Towell Perinatal Research Foundation (MGF); QTNPR (by CIHR) (LDD). Supported in part by Illumina Inc.

## **ACKNOWLEDGEMENTS**

The authors thank Dr. Jack Antel lab, especially Manon Blain, and Dr. Craig Moore for invaluable assistance with the cell culture protocol, St-Hyacinthe CHUV team for technical assistance and Jan Hamanishi for graphical design. We also thank Dr. Michael Dorschner lab for skilful assistance with RNA samples pipeline on the Illumina platform.



## Figure legends

**Figure 1. Experimental design of modulating  $\alpha 7$ nAChR signaling in a double-hit fetal sheep model.** *In vivo*, *in vitro* and RNAseq experiments are illustrated. *In vivo* study includes Control (saline) or LPS-exposed sheep fetuses. For the *in vitro* study, cultured cells were derived from an *in vivo* Control animal, named as Naïve or from an *in vivo* LPS-exposed animal, named as second hit (SH). There are 8 experimental groups: naïve Control (NC), naïve LPS (NL), naïve exposed to  $\alpha$ -Bungarotoxin (NB), naïve exposed to AR-R17779 (NA), and each respective second-hit groups (SH).

**Figure 2.** IL-1 $\beta$  secretion in ovine primary astrocyte cultures in response to six hours LPS exposure without or with pre-incubation with  $\alpha 7$ nAChR antagonist (B100) or agonist (A10) for one hour. Single hit, *in vitro* only LPS exposure; second hit, *in vivo* systemic and subsequent *in vitro* LPS exposure four to five weeks later. Y axis shows fold changes in IL-1 $\beta$  in relation to baseline secretion levels. GEE model results are presented in text and no significance marks are provided in the figure. Briefly, we found significant main term effects ( $p=0.019$ ) “treatment” (LPS and  $\alpha 7$ nAChR drug) as well as main term “hit” ( $p=0.010$ ), *i.e.*, the contribution of *in vivo* LPS exposure, the second hit effect on the IL-1 $\beta$  secretion profile.

**Figure 3.** Static 3D plot of the astrocyte RNA-Seq data with single and double-hit LPS treatment. The angle of the plot was chosen to give the best viewpoint to show differences between the sample types. Note that controls and  $\alpha 7$ nAChR agonistically pre-treated astrocytes cluster together and separately from those exposed to LPS w/o or with antagonistic  $\alpha 7$ nAChR pre-treatment.

**Table 1. Sample inventory for RNAseq study in astrocytes samples.**

**Table 2. Differentially expressed genes from the fetal sheep astrocytes whole transcriptome analysis: naïve and second hit astrocytes after modulation of  $\alpha 7$ nAChR signaling.** Differential analysis of count data was done with the edgeR package. Differentially expressed genes were selected, based on a 1.5-fold change and an FDR < 0.05. Up regulation and down regulation represent positive and negative log2 fold changes, respectively.

**Table 3. Comparison of astrocytes' and microglial transcriptomes**

**Table 4. Genes implicated in the signature of astrocytes and microglia exposed to endotoxin or maternal stress**

## References

1. Kalkman HO, Feuerbach D. Modulatory effects of  $\alpha 7$  nAChRs on the immune system and its relevance for CNS disorders. *Cell Mol Life Sci* (2016) **73**:2511–2530. doi:10.1007/s00018-016-2175-4
2. Cortes M, Cao M, Liu HL, Moore CS, Durosier LD, Burns P, Fecteau G, Desrochers A, Barreiro LB, Antel JP, et al.  $\alpha 7$  nicotinic acetylcholine receptor signaling modulates the inflammatory phenotype of fetal brain microglia: first evidence of interference by iron homeostasis. *Sci Rep* (2017) **7**:10645. doi:10.1038/s41598-017-09439-z
3. Kiguchi N, Kobayashi D, Saika F, Matsuzaki S, Kishioka S. Inhibition of peripheral macrophages by nicotinic acetylcholine receptor agonists suppresses spinal microglial activation and neuropathic pain in mice with peripheral nerve injury. *J Neuroinflammation* (2018) **15**:96. doi:10.1186/s12974-018-1133-5
4. Frasch MG, Szykaruk M, Prout AP, Nygard K, Cao M, Veldhuizen R, Hammond R, Richardson BS. Decreased neuroinflammation correlates to higher vagus nerve activity fluctuations in near-term ovine fetuses: a case for the afferent cholinergic anti-inflammatory pathway? *J Neuroinflammation* (2016) **13**:103. doi:10.1186/s12974-016-0567-x
5. Han Z, Li L, Wang L, Degos V, Maze M, Su H. Alpha-7 nicotinic acetylcholine receptor agonist treatment reduces neuroinflammation, oxidative stress, and brain injury in mice with ischemic stroke and bone fracture. *J Neurochem* (2014) **131**:498–508. Available at: <https://onlinelibrary.wiley.com/doi/abs/10.1111/jnc.12817>
6. de Jonge WJ, Ulloa L. The alpha7 nicotinic acetylcholine receptor as a pharmacological target for inflammation. *Br J Pharmacol* (2007) **151**:915–929. doi:10.1038/sj.bjp.0707264
7. Shytle RD, Mori T, Townsend K, Vendrame M, Sun N, Zeng J, Ehrhart J, Silver AA, Sanberg PR, Tan J. Cholinergic modulation of microglial activation by alpha 7 nicotinic receptors. *J Neurochem* (2004) **89**:337–343. doi:10.1046/j.1471-4159.2004.02347.x
8. Jassam YN, Izzy S, Whalen M, McGavern DB, El Khoury J. Neuroimmunology of Traumatic Brain Injury: Time for a Paradigm Shift. *Neuron* (2017) **95**:1246–1265. doi:10.1016/j.neuron.2017.07.010
9. Frasch MG, Nygard KL. Location, Location, Location: Appraising the Pleiotropic Function of HMGB1 in Fetal Brain. *J Neuropathol Exp Neurol* (2017) **76**:332–334. doi:10.1093/jnen/nlx004
10. Andersson U, Tracey KJ. HMGB1 is a therapeutic target for sterile inflammation and infection. *Annu Rev Immunol* (2011) **29**:139–162. doi:10.1146/annurev-immunol-030409-101323
11. Lange SC, Bak LK, Waagepetersen HS, Schousboe A, Norenberg MD. Primary cultures of astrocytes: their value in understanding astrocytes in health and disease. *Neurochem Res* (2012) **37**:2569–2588. doi:10.1007/s11064-012-0868-0

12. Sharma G, Vijayaraghavan S. Nicotinic cholinergic signaling in hippocampal astrocytes involves calcium-induced calcium release from intracellular stores. *Proc Natl Acad Sci U S A* (2001) **98**:4148–4153. doi:10.1073/pnas.071540198
13. Pedrazzi M, Patrone M, Passalacqua M, Ranzato E, Colamassaro D, Sparatore B, Pontremoli S, Melloni E. Selective proinflammatory activation of astrocytes by high-mobility group box 1 protein signaling. *J Immunol* (2007) **179**:8525–8532.
14. Barbierato M, Facci L, Argentini C, Marinelli C, Skaper SD, Giusti P. Astrocyte-microglia cooperation in the expression of a pro-inflammatory phenotype. *CNS Neurol Disord Drug Targets* (2013) **12**:608–618. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23574172>
15. Cheyuo C, Jacob A, Wu R, Zhou M, Coppa GF, Wang P. The parasympathetic nervous system in the quest for stroke therapeutics. *J Cereb Blood Flow Metab* (2011) **31**:1187–1195. doi:10.1038/jcbfm.2011.24
16. Cao J, Lu K-H, Powley TL, Liu Z. Vagal nerve stimulation triggers widespread responses and alters large-scale functional connectivity in the rat brain. *PLoS One* (2017) **12**:e0189518. doi:10.1371/journal.pone.0189518
17. Cortes M, Cao M, Liu HL, Burns P, Moore C, Fecteau G, Desrochers A, Barreiro LB, Antel JP, Frasch MG. RNAseq profiling of primary microglia and astrocyte cultures in near-term ovine fetus: A glial in vivo-in vitro multi-hit paradigm in large mammalian brain. *J Neurosci Methods* (2017) **276**:23–32. doi:10.1016/j.jneumeth.2016.11.008
18. Cao M, Cortes M, Moore CS, Leong SY, Durosier LD, Burns P, Fecteau G, Desrochers A, Auer RN, Barreiro LB, et al. Fetal microglial phenotype in vitro carries memory of prior in vivo exposure to inflammation. *Front Cell Neurosci* (2015) **9**:294. doi:10.3389/fncel.2015.00294
19. Frasch MG, Burns P, Benito J, Cortes M, Cao M, Fecteau G, Desrochers A. Sculpting the Sculptors: Methods for Studying the Fetal Cholinergic Signaling on Systems and Cellular Scales. *Methods Mol Biol* (2018) **1781**:341–352. doi:10.1007/978-1-4939-7828-1\_18
20. Patro R, Duggal G, Kingsford C. Salmon: Accurate, Versatile and Ultrafast Quantification from RNA-seq Data using Lightweight-Alignment. *bioRxiv* (2015)021592. doi:10.1101/021592
21. Soneson C, Love MI, Robinson MD. Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences. *F1000Res* (2015) **4**:1521. doi:10.12688/f1000research.7563.2
22. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics* (2010) **26**:139–140. doi:10.1093/bioinformatics/btp616
23. Lun ATL, Chen Y, Smyth GK. It's DE-licious: A Recipe for Differential Expression Analyses of RNA-seq Experiments Using Quasi-Likelihood Methods in edgeR. *Methods Mol Biol* (2016) **1418**:391–416. doi:10.1007/978-1-4939-3578-9\_19

24. Tyzack GE, Hall CE, Sibley CR, Cymes T, Forostyak S, Carlino G, Meyer IF, Schiavo G, Zhang S-C, Gibbons GM, et al. A neuroprotective astrocyte state is induced by neuronal signal EphB1 but fails in ALS models. *Nat Commun* (2017) **8**:1164. doi:10.1038/s41467-017-01283-z
25. Deak T, Kudinova A, Lovelock DF, Gibb BE, Hennessy MB. A multispecies approach for understanding neuroimmune mechanisms of stress. *Dialogues Clin Neurosci* (2017) **19**:37–53. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28566946>
26. Diz-Chaves Y, Astiz M, Bellini MJ, Garcia-Segura LM. Prenatal stress increases the expression of proinflammatory cytokines and exacerbates the inflammatory response to LPS in the hippocampal formation of adult male mice. *Brain Behav Immun* (2013) **28**:196–206. doi:10.1016/j.bbi.2012.11.013
27. Bronson SL, Bale TL. Prenatal stress-induced increases in placental inflammation and offspring hyperactivity are male-specific and ameliorated by maternal antiinflammatory treatment. *Endocrinology* (2014) **155**:2635–2646. doi:10.1210/en.2014-1040
28. Wu S, Gennings C, Wright RJ, Wilson A, Burris HH, Just AC, Braun JM, Svensson K, Zhong J, Brennan KJM, et al. Prenatal Stress, Methylation in Inflammation-Related Genes, and Adiposity Measures in Early Childhood: the Programming Research in Obesity, Growth Environment and Social Stress Cohort Study. *Psychosom Med* (2018) **80**:34–41. doi:10.1097/PSY.0000000000000517
29. Shapiro GD, Fraser WD, Frasch MG, Séguin JR. Psychosocial stress in pregnancy and preterm birth: associations and mechanisms. *J Perinat Med* (2013) **41**:631–645. doi:DOI 10.1515/jpm-2012-0295
30. Christian LM, Franco A, Glaser R, Iams JD. Depressive symptoms are associated with elevated serum proinflammatory cytokines among pregnant women. *Brain Behav Immun* (2009) **23**:750–754. doi:10.1016/j.bbi.2009.02.012
31. El-Ansary A, Al-Ayadhi L. Neuroinflammation in autism spectrum disorders. *J Neuroinflammation* (2012) **9**:265. doi:10.1186/1742-2094-9-265
32. Kinney DK, Munir KM, Crowley DJ, Miller AM. Prenatal stress and risk for autism. *Neurosci Biobehav Rev* (2008) **32**:1519–1532. doi:10.1016/j.neubiorev.2008.06.004
33. Barros VG, Duhalde-Vega M, Caltana L, Brusco A, Antonelli MC. Astrocyte-neuron vulnerability to prenatal stress in the adult rat brain. *J Neurosci Res* (2006) **83**:787–800. doi:10.1002/jnr.20758
34. Barros VG, Berger MA, Martijena ID, Sarchi MI, Perez AA, Molina VA, Tarazi FI, Antonelli MC. Early adoption modifies the effects of prenatal stress on dopamine and glutamate receptors in adult rat brain. *J Neurosci Res* (2004) **76**:488–496. doi:10.1002/jnr.20119
35. Jauregui-Huerta F, Ruvalcaba-Delgadillo Y, Gonzalez-Castañeda R, Garcia-Estrada J, Gonzalez-Perez O, Luquin S. Responses of glial cells to stress and glucocorticoids. *Curr Immunol Rev* (2010) **6**:195–204. doi:10.2174/157339510791823790

36. Autry AE, Grillo CA, Piroli GG, Rothstein JD, McEwen BS, Reagan LP. Glucocorticoid regulation of GLT-1 glutamate transporter isoform expression in the rat hippocampus. *Neuroendocrinology* (2006) **83**:371–379. doi:10.1159/000096092
37. Reagan LP, Rosell DR, Wood GE, Spedding M, Muñoz C, Rothstein J, McEwen BS. Chronic restraint stress up-regulates GLT-1 mRNA and protein expression in the rat hippocampus: reversal by tianeptine. *Proc Natl Acad Sci U S A* (2004) **101**:2179–2184. doi:10.1073/pnas.0307294101
38. Zschocke J, Bayatti N, Clement AM, Witan H, Figiel M, Engele J, Behl C. Differential promotion of glutamate transporter expression and function by glucocorticoids in astrocytes from various brain regions. *J Biol Chem* (2005) **280**:34924–34932. doi:10.1074/jbc.M502581200
39. Srinivasan D, Yen J-H, Joseph DJ, Friedman W. Cell Type-Specific Interleukin-1 $\beta$  Signaling in the CNS. *J Neurosci* (2004) **24**:6482–6488. doi:10.1523/JNEUROSCI.5712-03.2004
40. Fischbach GD, Lord C. The Simons Simplex Collection: A Resource for Identification of Autism Genetic Risk Factors. *Neuron* (2010) **68**:192–195. doi:10.1016/j.neuron.2010.10.006
41. Lee YS, Wollam J, Olefsky JM. An Integrated View of Immunometabolism. *Cell* (2018) **172**:22–40. doi:10.1016/j.cell.2017.12.025
42. Camandola S. Astrocytes, emerging stars of energy homeostasis. *Cell Stress Chaperones* (2018) **2**:246–252. doi:10.15698/cst2018.10.157
43. Satoh J-I, Kino Y, Asahina N, Takitani M, Miyoshi J, Ishida T, Saito Y. TMEM119 marks a subset of microglia in the human brain. *Neuropathology* (2016) **36**:39–49. doi:10.1111/neup.12235
44. Bennett ML, Bennett FC, Liddel SA, Ajami B, Zamanian JL, Fernhoff NB, Mulinyawe SB, Bohlen CJ, Adil A, Tucker A, et al. New tools for studying microglia in the mouse and human CNS. *Proc Natl Acad Sci U S A* (2016) **113**:E1738–46. doi:10.1073/pnas.1525528113
45. Butovsky O, Jedrychowski MP, Moore CS, Cialic R, Lanser AJ, Gabriely G, Koeglspenger T, Dake B, Wu PM, Doykan CE, et al. Identification of a unique TGF-beta-dependent molecular and functional signature in microglia. *Nat Neurosci* (2014) **17**:131–143. doi:10.1038/nn.3599
46. Abud EM, Ramirez RN, Martinez ES, Healy LM, Nguyen CHH, Newman SA, Yeromin AV, Scarfone VM, Marsh SE, Fimbres C, et al. iPSC-Derived Human Microglia-like Cells to Study Neurological Diseases. *Neuron* (2017) **94**:278–293.e9. doi:10.1016/j.neuron.2017.03.042
47. Dipasquale V, Cutrupi MC, Colavita L, Manti S, Cuppari C, Salpietro C. Neuroinflammation in Autism Spectrum Disorders: Role of High Mobility Group Box 1 Protein. *Int J Mol Cell Med* (2017) **6**:148–155. doi:10.22088/acadpub.BUMS.6.3.148

48. Lobo-Silva D, Carriche GM, Castro AG, Roque S, Saraiva M. Balancing the immune response in the brain: IL-10 and its regulation. *J Neuroinflammation* (2016) **13**:297. doi:10.1186/s12974-016-0763-8
49. Saresella M, Piancone F, Marventano I, Zoppis M, Hernis A, Zanette M, Trabattoni D, Chiappedi M, Ghezzi A, Canevini MP, et al. Multiple inflammasome complexes are activated in autistic spectrum disorders. *Brain Behav Immun* (2016) **57**:125–133. doi:10.1016/j.bbi.2016.03.009
50. Tsilioni I, Dodman N, Petra AI, Taliou A, Francis K, Moon-Fanelli A, Shuster L, Theoharides TC. Elevated serum neurotensin and CRH levels in children with autistic spectrum disorders and tail-chasing Bull Terriers with a phenotype similar to autism. *Transl Psychiatry* (2014) **4**:e466. doi:10.1038/tp.2014.106
51. Theoharides TC, Asadi S, Patel AB. Focal brain inflammation and autism. *J Neuroinflammation* (2013) **10**:46. doi:10.1186/1742-2094-10-46
52. Wyrwoll CS, Holmes MC, Seckl JR. 11 $\beta$ -hydroxysteroid dehydrogenases and the brain: from zero to hero, a decade of progress. *Front Neuroendocrinol* (2011) **32**:265–286. doi:10.1016/j.yfrne.2010.12.001
53. Lemche E, Chaban OS, Lemche AV. Neuroendocrine and Epigenetic Mechanisms Subservicing Autonomic Imbalance and HPA Dysfunction in the Metabolic Syndrome. *Front Neurosci* (2016) **10**:142. doi:10.3389/fnins.2016.00142
54. Yang P-C, Yang C-H, Huang C-C, Hsu K-S. Phosphatidylinositol 3-kinase activation is required for stress protocol-induced modification of hippocampal synaptic plasticity. *J Biol Chem* (2008) **283**:2631–2643. doi:10.1074/jbc.M706954200
55. Shi H-S, Zhu W-L, Liu J-F, Luo Y-X, Si J-J, Wang S-J, Xue Y-X, Ding Z-B, Shi J, Lu L. PI3K/Akt signaling pathway in the basolateral amygdala mediates the rapid antidepressant-like effects of trefoil factor 3. *Neuropsychopharmacology* (2012) **37**:2671–2683. doi:10.1038/npp.2012.131
56. Contreras JE, Sánchez HA, Eugenin EA, Speidel D, Theis M, Willecke K, Bukauskas FF, Bennett MVL, Sáez JC. Metabolic inhibition induces opening of unapposed connexin 43 gap junction hemichannels and reduces gap junctional communication in cortical astrocytes in culture. *Proc Natl Acad Sci U S A* (2002) **99**:495–500. doi:10.1073/pnas.012589799
57. Frasch MG. Putative Role of AMPK in Fetal Adaptive Brain Shut-Down: Linking Metabolism and Inflammation in the Brain. *Front Neurol* (2014) **5**:150. doi:10.3389/fneur.2014.00150
58. Hui K, Katayama Y, Nakayama KI, Nomura J, Sakurai T. Characterizing vulnerable brain areas and circuits in mouse models of autism: Towards understanding pathogenesis and new therapeutic approaches. *Neurosci Biobehav Rev* (2018). doi:10.1016/j.neubiorev.2018.08.001
59. Wang H, Doering LC. Reversing autism by targeting downstream mTOR signaling. *Front Cell Neurosci* (2013) **7**:28. doi:10.3389/fncel.2013.00028

60. Hua S, Ek CJ, Mallard C, Johansson ME. Perinatal hypoxia-ischemia reduces alpha 7 nicotinic receptor expression and selective alpha 7 nicotinic receptor stimulation suppresses inflammation and promotes microglial Mox phenotype. *Biomed Res Int* (2014) **2014**:718769. doi:10.1155/2014/718769
61. Noris M, Remuzzi G. Overview of complement activation and regulation. *Semin Nephrol* (2013) **33**:479–492. doi:10.1016/j.semnephrol.2013.08.001
62. Schafer DP, Lehrman EK, Kautzman AG, Koyama R, Mardinly AR, Yamasaki R, Ransohoff RM, Greenberg ME, Barres BA, Stevens B. Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. *Neuron* (2012) **74**:691–705. doi:10.1016/j.neuron.2012.03.026
63. Hong S, Beja-Glasser VF, Nfonoyim BM, Frouin A, Li S, Ramakrishnan S, Merry KM, Shi Q, Rosenthal A, Barres BA, et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. *Science* (2016) **352**:712–716. doi:10.1126/science.aad8373
64. Thorsell A. Brain neuropeptide Y and corticotropin-releasing hormone in mediating stress and anxiety. *Exp Biol Med* (2010) **235**:1163–1167. doi:10.1258/ebm.2010.009331
65. Sailaja BS, Cohen-Carmon D, Zimmerman G, Soreq H, Meshorer E. Stress-induced epigenetic transcriptional memory of acetylcholinesterase by HDAC4. *Proc Natl Acad Sci U S A* (2012) **109**:E3687–95. doi:10.1073/pnas.1209990110
66. Lord C, Risi S, Lambrecht L, Cook EH Jr, Leventhal BL, DiLavore PC, Pickles A, Rutter M. The autism diagnostic observation schedule-generic: a standard measure of social and communication deficits associated with the spectrum of autism. *J Autism Dev Disord* (2000) **30**:205–223. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/11055457>
67. Lord C, Rutter M, Le Couteur A. Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. *J Autism Dev Disord* (1994) **24**:659–685.
68. American Psychiatric Association. *Desk Reference to the Diagnostic Criteria From DSM-IV-TR*. American Psychiatric Publishing (2000). Available at: [https://books.google.com/books/about/Desk\\_Reference\\_to\\_the\\_Diagnostic\\_Criteri.html?hl=&id=Dp10tAEACAAJ](https://books.google.com/books/about/Desk_Reference_to_the_Diagnostic_Criteri.html?hl=&id=Dp10tAEACAAJ)
69. Iossifov I, O’Roak BJ, Sanders SJ, Ronemus M, Krumm N, Levy D, Stessman HA, Witherspoon KT, Vives L, Patterson KE, et al. The contribution of de novo coding mutations to autism spectrum disorder. *Nature* (2014) **515**:216–221. doi:10.1038/nature13908
70. Sanders SJ, He X, Willsey AJ, Ercan-Sencicek AG, Samocha KE, Cicek AE, Murtha MT, Bal VH, Bishop SL, Dong S, et al. Insights into Autism Spectrum Disorder Genomic Architecture and Biology from 71 Risk Loci. *Neuron* (2015) **87**:1215–1233. doi:10.1016/j.neuron.2015.09.016
71. Jin Y, Kong J. Transcutaneous Vagus Nerve Stimulation: A Promising Method for Treatment of Autism Spectrum Disorders. *Front Neurosci* (2016) **10**:609.



doi:10.3389/fnins.2016.00609

72. Andersson U, Tracey KJ. Reflex principles of immunological homeostasis. *Annu Rev Immunol* (2012) **30**:313–335. doi:10.1146/annurev-immunol-020711-075015
73. Frasca M, Prout A, Szyndrak M, Gagnon R, Richardson B. Cholinergic anti-inflammatory pathway mechanisms may be active in the pre-term ovine fetus. *Reprod Sci* (2009) **16**:137A.
74. Frasca MG, Nygard K, Vittal P, Zhao L, Regnault TR, Richardson BS. Translocation of neuronal high-mobility group box1 protein in relation to microglial activation in fetal sheep following repetitive umbilical cord occlusions with severe hypoxic-acidemia. *Reprod Sci* (2010) **17**:Accepted for Society for Gynecological Investigation meeting.
75. Nygard K, Vittal P, Richardson BS, Frasca MG. Fetal cholinergic anti-inflammatory pathway and the neuronal and astrocytic high-mobility group box 1 (HMGB1) protein release during cerebral inflammatory response. *Reprod Sci* (2011) **17**(3) (Suppl):51A.
76. Furukawa S, Sameshima H, Yang L, Ikenoue T. Activation of acetylcholine receptors and microglia in hypoxic-ischemic brain damage in newborn rats. *Brain Dev* (2013) **35**:607–613. doi:10.1016/j.braindev.2012.10.006
77. Furukawa S, Sameshima H, Yang L, Ikenoue T. Acetylcholine receptor agonist reduces brain damage induced by hypoxia-ischemia in newborn rats. *Reprod Sci* (2011) **18**:172–179. doi:10.1177/1933719110385129
78. Baier CJ, Pallares ME, Adrover E, Monteleone MC, Brocco MA, Barrantes FJ, Antonelli MC. Prenatal restraint stress decreases the expression of alpha-7 nicotinic receptor in the brain of adult rat offspring. *Stress* (2015) **18**:435–445. doi:10.3109/10253890.2015.1022148
79. Adrover E, Pallarés ME, Baier CJ, Monteleone MC, Giuliani FA, Waagepetersen HS, Brocco MA, Cabrera R, Sonnewald U, Schousboe A, et al. Glutamate neurotransmission is affected in prenatally stressed offspring. *Neurochem Int* (2015) **88**:73–87. doi:10.1016/j.neuint.2015.05.005
80. Elovitz MA, Brown AG, Breen K, Anton L, Maubert M, Burd I. Intrauterine inflammation, insufficient to induce parturition, still evokes fetal and neonatal brain injury. *Int J Dev Neurosci* (2011) **29**:663–671. doi:10.1016/j.ijdevneu.2011.02.011
81. Ghazalpour A, Bennett B, Petyuk VA, Orozco L, Hagopian R, Mungrue IN, Farber CR, Sinsheimer J, Kang HM, Furlotte N, et al. Comparative analysis of proteome and transcriptome variation in mouse. *PLoS Genet* (2011) **7**:e1001393. doi:10.1371/journal.pgen.1001393
82. Rothhammer V, Borucki DM, Tjon EC, Takenaka MC, Chao C-C, Ardura-Fabregat A, de Lima KA, Gutiérrez-Vázquez C, Hewson P, Staszewski O, et al. Microglial control of astrocytes in response to microbial metabolites. *Nature* (2018) **557**:724–728. doi:10.1038/s41586-018-0119-x

83. Cumberland AL, Palliser HK, Rani P, Walker DW, Hirst JJ. Effects of combined IUGR and prenatal stress on the development of the hippocampus in a fetal guinea pig model. *J Dev Orig Health Dis* (2017) **8**:584–596. doi:10.1017/s2040174417000307
84. Farrokhi CB, Tovote P, Blanchard RJ, Blanchard DC, Litvin Y, Spiess J. Cortagine: behavioral and autonomic function of the selective CRF receptor subtype 1 agonist. *CNS Drug Rev* (2007) **13**:423–443. doi:10.1111/j.1527-3458.2007.00027.x